Drug
Ak112 Oxaliplatin Capecitabine
Ak112 Oxaliplatin Capecitabine: highest development phase Phase 2, developed by Akeso. 1 trial record tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- Akeso
Trials
| Drug | Phase | Indication |
|---|---|---|
| AK112+oxaliplatin+capecitabine NCT07091227 | Phase 2 | Gastric or Gastroesophageal Junction Adenocarcinoma |
Latest
No recent events.
Follow Ak112 Oxaliplatin Capecitabine on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.